Shield Therapeutics PLC Notice of Results (9623N)
August 15 2017 - 2:00AM
UK Regulatory
TIDMSTX
RNS Number : 9623N
Shield Therapeutics PLC
15 August 2017
Shield Therapeutics plc
("Shield" or the "Group")
Notice of Results
London, UK, 15 August 2017: Shield Therapeutics (LSE: STX), a
specialty pharmaceutical company focused on secondary care,
announces it will report its interim results for the six months
ended 30 June 2017 on Wednesday 20 September 2017.
Shield will host a presentation and conference call for analysts
at 9.30am BST on the morning of the results in the Guildhall Room
at 85 Gresham Street, London, EC2V 7NQ.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)20 7186 8500
Carl Sterritt, Chief Executive Officer
Joanne Estell, Chief Financial Officer
Karl Keegan, Director Corporate Development
Nominated Adviser and Joint Broker +44 (0)20 3100 2222
Liberum Capital Limited
Christopher Britton
Steve Pearce
Jonathan Wilkes-Green
Joint Broker +44 (0)20 7418 8900
Peel Hunt LLP
James Steel
Alastair Rae
Oliver Jackson
Financial PR Advisor +44 (0) 203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott
Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals which address areas of unmet
medical need. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru(R), for the treatment of iron deficiency anaemia
(IDA) in adult patients with inflammatory bowel disease (IBD) which
has exclusive IP rights until the mid-2030's. In addition, the
Group is developing PT20, a late-stage pharmaceutical for the
treatment of systemic phosphate accumulation (hyperphosphatemia).
Shield Therapeutics, headquartered in London, is listed on LSE's
AIM under the ticker STX. For more information please visit
www.shieldtx.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBUGDIIXBBGRS
(END) Dow Jones Newswires
August 15, 2017 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024